Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Scheduled to Post Earnings on Wednesday
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will be posting its quarterly earnings results on Wednesday, August 2nd. Analysts expect Adamas Pharmaceuticals to post earnings of ($0.81) per share for the quarter.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 45.19%. During the same period in the previous year, the firm posted ($0.65) earnings per share. On average, analysts expect Adamas Pharmaceuticals to post $-3.47 EPS for the current fiscal year and $-2.37 EPS for the next fiscal year.
Adamas Pharmaceuticals, Inc. (NASDAQ ADMS) opened at 18.26 on Wednesday. The firm has a 50-day moving average of $17.34 and a 200-day moving average of $16.84. Adamas Pharmaceuticals, Inc. has a 1-year low of $12.10 and a 1-year high of $19.50. The stock’s market cap is $408.28 million.
ADMS has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Cowen and Company reiterated an “outperform” rating and set a $45.00 price objective on shares of Adamas Pharmaceuticals in a research report on Sunday, May 28th. Mizuho reiterated a “buy” rating and set a $26.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, May 12th. Finally, BidaskClub cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $29.00.
In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $17.08, for a total value of $6,490,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/26/adamas-pharmaceuticals-inc-nasdaqadms-scheduled-to-post-earnings-on-wednesday.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.